Vivoryon Therapeutics N.V.
0R3M.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.1M
Close$
$0.20
79.8% downside
Current Fair Value
79.8% downsideOvervalued by 79.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.10 Million |
|---|---|
| Enterprise Value | $28.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.33 |
| Beta | 1.45 |
| Outstanding Shares | 29,614,327 |
Return
| Return on Equity | -1230.03% |
|---|---|
| Return on Assets | -461.96% |
| Return on Invested Capital | -560.42% |
Valuation & Multiples
| P/E Ratio | -4.57 |
|---|---|
| PEG | 11.98 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.47 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vivoryon Therapeutics N.V.
14 employees
CEO: Frank T. Weber Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for Alzheimer's disease. Their primary strategy involves targeting and inhibiting the production of toxic p...